Skip to main
GRDN
GRDN logo

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Services Inc. has demonstrated a strong position in the market due to its advanced technology capabilities, which are expected to enhance value-based care discussions and drive integration efficiencies from recent acquisitions. The company's focus on tailored services for lower acuity long-term care facilities, along with a substantial market share of its pharmacies, highlights its competitive differentiation in the sector. Furthermore, the implementation of robotic dispensing technology has increased operational efficiencies, significantly reducing the time to fill requisitions to less than one day, which underscores the company's commitment to improving service delivery and clinical outcomes.

Bears say

Guardian Pharmacy Services Inc. faces significant risks that may adversely impact its financial performance and stock outlook, including potential changes in regulatory and reimbursement frameworks, particularly under the Inflation Reduction Act (IRA). The company's reliance on effective relationships with long-term care facilities (LTCFs) is critical, yet current management issues may threaten these relationships and lead to supply chain disruptions. Additionally, challenges in hiring and retaining clinical staff, sourcing, and integrating acquisitions along with heavy dependence on technology assets create further uncertainties that could hinder business operations and overall growth prospects.

GRDN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 2 analysts, GRDN has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.